Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicity

Key Points

• To investigate the occurrence of tumor flare pain reactions following treatment with bispecific T-cell engagers in patients with multiple myeloma.
• Clinical observations of patients treated with bispecific T-cell engagers for multiple myeloma.
• Assessment of reported pain reactions post-treatment.
• Evaluation of patient records for evidence of tumor flare reactions.
• Increased reports of tumor flare pain reactions after bispecific T-cell engager administration.
• Identification of this pain reaction as a significant but often overlooked toxicity.
• Recommendations for improved monitoring and management of associated symptoms in clinical settings.